These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18466432)

  • 1. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients.
    Pescovitz MD; Knechtle S; Alexander SR; Colombani P; Nevins T; Nieforth K; Bouw MR
    Pediatr Transplant; 2008 Jun; 12(4):447-55. PubMed ID: 18466432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Ekberg H; Tedesco-Silva H; Demirbas A; Vítko S; Nashan B; Gürkan A; Margreiter R; Hugo C; Grinyó JM; Frei U; Vanrenterghem Y; Daloze P; Halloran PF;
    N Engl J Med; 2007 Dec; 357(25):2562-75. PubMed ID: 18094377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids.
    Hesselink DA; Ngyuen H; Wabbijn M; Gregoor PJ; Steyerberg EW; van Riemsdijk IC; Weimar W; van Gelder T
    Br J Clin Pharmacol; 2003 Sep; 56(3):327-30. PubMed ID: 12919182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
    Washburn K; Speeg KV; Esterl R; Cigarroa F; Pollack M; Tourtellot C; Maxwell P; Halff G
    Transplantation; 2001 Nov; 72(10):1675-9. PubMed ID: 11726831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation.
    Ekberg H; Persson NH; Källen R; Gül-Baykurt N
    Scand J Immunol; 2003 Dec; 58(6):670-7. PubMed ID: 14636424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
    Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
    Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
    Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
    Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
    Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
    Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
    Ingle GR; Moudgil A; Vo A; Jordan SC
    Am J Health Syst Pharm; 2005 Feb; 62(4):391-6. PubMed ID: 15745891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
    Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
    Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.
    Klintmalm GB; Washburn WK; Rudich SM; Heffron TG; Teperman LW; Fasola C; Eckhoff DE; Netto GJ; Katz E
    Liver Transpl; 2007 Nov; 13(11):1521-31. PubMed ID: 17969201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M; Ming A; Zhao M
    Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients.
    Ciancio G; Burke GW; Suzart K; Mattiazzi A; Vaidya A; Roth D; Kupin W; Rosen A; Johnson N; Miller J
    Am J Transplant; 2003 Aug; 3(8):1010-6. PubMed ID: 12859538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study.
    Neuberger JM; Mamelok RD; Neuhaus P; Pirenne J; Samuel D; Isoniemi H; Rostaing L; Rimola A; Marshall S; Mayer AD;
    Am J Transplant; 2009 Feb; 9(2):327-36. PubMed ID: 19120077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
    Mastrobuoni S; Ubilla M; Cordero A; Herreros J; Rabago G
    Transplant Proc; 2007 Sep; 39(7):2163-6. PubMed ID: 17889125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients.
    Silverstein DM; Aviles DH; LeBlanc PM; Jung FF; Vehaskari VM
    Pediatr Transplant; 2005 Oct; 9(5):589-97. PubMed ID: 16176415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants.
    Ciancio G; Mattiazzi A; Roth D; Kupin W; Miller J; Burke GW
    Clin Transplant; 2003 Oct; 17(5):428-32. PubMed ID: 14703925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year follow-up of malignancies in tacrolimus-treated renal recipients--an analysis of European multicentre studies.
    Cowlrick I; Delventhal H; Kaipainen K; Krcmar C; Petan J; Schleibner S
    Clin Transplant; 2008; 22(3):372-7. PubMed ID: 18279418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
    Stratta RJ; Alloway RR; Lo A; Hodge E
    Transplantation; 2003 Apr; 75(8):1260-6. PubMed ID: 12717213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.